Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
14C Epaminurad Mass Balance Study in Healthy Male Subjects
NCT07036458Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epaminurad in gout, sponsored by JW Pharmaceutical Corporation. Primary endpoints: Mass balance recovery of total radioactivity in all excreta at Day 8 and Metabolite profiling and structural identification at Day 8. Started Aug 2025; status: completed.
02
Drugs
epaminurad
03
Conditions
gout
Beyond the preview
Go deeper on NCT07036458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07036458.